Chow L.W.C.

1

CURRICULUM VITAE

PERSONAL PARTICULARS

NAME: Louis Wing-Cheong CHOW

SEX: Male

QUALIFICATIONS

Basic Qualification: M.B.B.S. (HK) May 1984

Postgraduate Qualifications: F.R.C.S. (Glasgow) May 1988

F.C.S. (HK) December 1990

F.H.K.A.M.(Surgery) December 1993

M.S. (HKU) December 1999

F.A.C.S. October 2004

SABBATICAL TRAINING

Breast Service Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

Jul – Nov 1994

Division of Surgical Oncology Department of Surgery, University of Southern California, Los Angeles, USA

Jan 1993

Division of Surgical Oncology Department of Surgery, Yale University, USA

Oct – Dec 1992

Gastric & Mixed Tumors Service Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

Jul – Sep 1992

PRESENT APPOINTMENTS

Visiting Professor Wuhan University of Science and Technology P.R. China

Oct 2008 – present

Honorary Consultant Kiang Wu Hospital, Macau SAR

Feb 2008 – present

Honorary Professor Ningxia Medical College School of Clinical Medicine , Ningxia, P.R. China

Dec 2007 - present

Medical Director Comprehensive Centre for Breast Diseases UNIMED Medical Institute, Hong Kong SAR

Jan 2006 – present

Honorary Professor Tohoku University, Sendai, Japan

Apr 2004 – present

Chow L.W.C.

2

PRESENT APPOINTMENTS IN PROFESSIONAL ASSOCIATIONS

Editorial Board Member Breast Case

Sep 2011 – present

Editorial Board Member Chinese Journal of Clinicians (CJC)

Aug 2010 – present

Executive Board Member European-Asian Society for Breast Disease (EURAMA)

Jun 2010 – present

Editorial Board Member Journal of Angiogenesis Research

May 2010 – present

Editorial Board Member Chinese Journal of Cancer Research

Jan 2010 – present

Executive Committee Member Chinese Society of Clinical Oncology

Oct 2009 – present

Deputy Editor-in-Chief Editorial Board, Chinese Journal of Breast Disease (Electronic

Edition)

Oct 2008 – present

Vice-Chairman Breast Group, Oncology Branch, Chinese Medical Association

Oct 2008 – present

Executive Chief Editor Editorial Board, Chinese Journal of Traditional and Western Medicine

Jul 2007 – present

Executive Director Organisation for Oncology and Translational Research

Dec 2002 – present

Executive Member Asian Breast Cancer Society

Apr 1999 – present

PREVIOUS APPOINTMENTS

Honorary Secretary The Hong Kong Academy of Medicine, Hong Kong SAR

Dec 2008 – 2012

Honorary Clinical Professor Clinical Trials Centre, Li Ka Shing Faculty of Medicine The University of Hong Kong, Hong Kong SAR

Nov 2008 – 2012

Member Steering Committee on e-Health Record Sharing Food and Health Bureau, Government Secretariat , Hong Kong SAR

Jul 2007 – 2012

Member Task Group on Breast Cancer Management Hospital Authority, Hong Kong SAR

Mar 2002 – 2004

Member Task Group on Re-development of Li Shu Fan Building The University of Hong Kong, Hong Kong SAR

Jul 2001 – Dec 2001

Chow L.W.C.

3

Honorary Secretary Hong Kong Association for Integration of Chinese-Western Medicine

Feb 2001 – Dec 2004

Director Hung Chao Hong Integrated Centre for Breast Diseases Tung Wah Hospital, Hong Kong SAR

Jan 2001 – Dec 2005

Editor Medical Faculty News, Faculty of Medicine The University of Hong Kong, Hong Kong SAR

Jun 2000 – Dec 2005

Associate Dean (Community Relations) Faculty of Medicine The University of Hong Kong, Hong Kong SAR

Jan 2000 – Mar 2001

Member Board of Studies, School of Chinese Medicine The University of Hong Kong, Hong Kong SAR

Sep 1999 – Dec 2005

Deputy Director Centre of Education and Training, Department of Surgery The University of Hong Kong, Hong Kong SAR

Jun 1999 – Dec 2005

Board Member Steering Committee, Clinical Trial Centre The University of Hong Kong, Hong Kong SAR

Jan 1999 – Jun 1999

Fellow, Centre of Endocrinology and Diabetes The University of Hong Kong, Hong Kong SAR

Sep 1998 – Dec 2005

Fellow, Cancer Research Centre The University of Hong Kong, Hong Kong SAR

Sep 1998 – Dec 2005

Chairman Clinical Skills Planning Group New Medical Curriculum

Jun 1998 – Dec 2005

Associate Professor Department of Surgery The University of Hong Kong, Hong Kong SAR

Mar 1997 – Dec 2005

Honorary Consultant Department of Surgery, Tung Wah Hospital, Hong Kong SAR

Jul 1996 – Dec 2005

Honorary Consultant Department of Surgery, Queen Mary Hospital, Hong Kong SAR

Jul 1996 – Dec 2005

Chief, Division of Breast Surgery The University of Hong Kong, Hong Kong SAR

Jul 1995 – Dec 2005

Assistant Professor Department of Surgery, The University of Hong Kong, Hong Kong SAR

Apr 1993 – Mar 1997

Chow L.W.C.

4

PREVIOUS APPOINTMENTS IN PROFESSIONAL ASSOCIATIONS

President (Asia-Africa) Senologic International Society (SIS)

2008 – 2009

Vice-President Hong Kong Day Surgery Association

Jun 2000 – 2011

President Asian Breast Cancer Society

Oct 1999 – Sep 2000

Honorary Secretary Hong Kong Day Surgery Association

Jul 1995 – Jun 1997

Honorary Secretary University Medical Doctors’ Association

Jul 1995 – Jun 1997

Council Member Public Doctor Association, Hong Kong SAR

Jul 1995 – Jun 1997

PROFESSIONAL MEMBERSHIP

Hong Kong: Hong Kong Medical Association

International: International Society of Surgery American Association of Cancer Research Asian Surgical Association American Society of Breast Disease Breast Surgery International American Society of Breast Surgeons

TEACHING DUTIES AND EXPERIENCE

Courses Attended Breast Sonography Program Institute of Ultrasound, St Peterburg, Florida, USA

Jun 2004

Radioguided Surgery and Minimally Invasive Breast Biopsy H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

Jun 2001

Program for Advanced Medical Education Harvard Medical School, Boston, USA

Dec 1999

Courses Taught Radioguided Surgery Course, Chengdu Department of Surgery Xua Shi Medical School, P.R. China

Nov 2003

Breast Cancer Understanding Cancer Broadening Courses in Culture and Value Studies and Theme Studies The University of Hong Kong

1999 – present

Chow L.W.C.

5

Principles of Surgical Treatment of Cancer Understanding Cancer Broadening Courses in Culture and Value Studies and Theme Studies The University of Hong Kong

1999 – present

Management of Advanced Stage Breast Cancer Diploma in Oncology & Palliative Care for Health Care Professionals School of Professional & Continuing Education, The University of Hong Kong

Dec 1998

Breast Cancer – Screening & Surgical Treatment Diploma in Oncology & Palliative Care for Health Care Professionals School of Professional & Continuing Education, The University of Hong Kong

Jul 1997

Mock Viva on Breast Diseases Advanced Course in Surgery Department of Surgery, The University of Hong Kong

Jul 1997

Management of Breast Cancer Advanced Course in Surgery Department of Surgery, The University of Hong Kong

Jul 1997

Breast Cancer Certificate Course in Clinical Oncology Department of Nursing Studies, The University of Hong Kong

Apr 1997

Surgery and Breast Cancer Advanced Course in Breast Cancer Nursing, Hong Kong SAR

Aug 1996

Classification and Staging of Breast Cancer Advanced Course in Breast Cancer Nursing, Hong Kong SAR

Aug 1996

Seminars and Interactive Teaching

Tutor, Health Care Project for Phase I Students Faculty of Medicine, The University of Hong Kong,

2001 – present

Lecturer, whole class session on “Breast Mass” Phase I Department of Surgery, The University of Hong Kong,

Chief Co-ordinator of Teaching in Network Hospitals Phase II, Block B, Department of Surgery, The University of Hong Kong,

1998 – present

Chief Co-ordinator of Teaching Clinic Phase I, Block B, Department of Surgery, The University of Hong Kong,

1998 – present

PBL Tutor Phase I, Block B Department of Surgery, The University of Hong Kong,

1997 – present

PBL – Case Writer of Breast Cancer Phase I, Block B, Department of Surgery, The University of Hong Kong,

1997 – present

Interactive Teaching on Breast Diseases Junior Clinical Clerkship Department of Surgery, The University of Hong Kong,

1996 – 1999

Chow L.W.C.

6

Clinical Demonstration on Breast Examination Introductory Clinical Course Department of Surgery, The University of Hong Kong,

1995 – present

Seminars and Tutorials Special Clinical Clerkship Department of Surgery, The University of Hong Kong,

1995 – 1999

Course Director

Minimally Invasive Breast Biopsy Course Department of Surgery, The University of Hong Kong,

Nov 2004

Radioguided Surgery Course for Breast Cancer Department of Surgery, The University of Hong Kong,

Jun 2004

Radioguided Surgery Course for Breast Cancer Department of Surgery, The University of Hong Kong,

Nov 2003

Radioguided Surgery Course for Breast Cancer Department of Surgery, The University of Hong Kong,

Nov 2002

Radioguided Surgery Course for Breast Cancer Department of Surgery, The University of Hong Kong,

Mar 2002

Summer Broadening Course Faculty of Medicine, The University of Hong Kong,

2001

Summer Broadening Course Faculty of Medicine, The University of Hong Kong,

2000

RESEARCH ACTIVITIES

Thesis

Master of Surgery Modification of acute inflammatory response phase response caused by surgical trauma in a mastectomy model

Degree conferred in December 1999

Journal Articles Published

1. Case report: postradiation chondrosarcoma with a short latency period of 6 months Yang S, Tang W, Tang XF, Xuan M, Guo LJ, Wang XY, Loo WT, Liu Q, Chow LW, Cheung MN, Tsang W Int J Biol Markers 2014 Nov 8:0

2. Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y, Shen KW, Chow LW, Loo WT, Chow CY, Tsang W Int J Biol Markers 2014 Nov 5:0

3. Suppression of C6 gliomas via application of rat hyperplasia gene. Gao P, Wang Z, Zhang B, Zou Y, Guo H, Liu H, Yang Q, Fang Z, Jiang S, Shen B, Chow LW, Loo WT, Ng EL, Tsang WW. Int J Biol Markers. 2014 Oct 8:0. doi: 10.5301/jbm.5000114.

Chow L.W.C.

7

4. Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of status of chronic inflammation and cancer. Wang YJ, He L, Yuan M, Tsang WW, Hao L, Wang M, Chow LW, Cheung MN, Liu Q, Ng EL, Loo WT, Chow CY, Bai LJ, Yang Z. Int J Biol Markers. 2014 Sep 30;29(3):e208-14. doi: 10.5301/jbm.5000104.

5. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients Chan MS, Chen SF, Felizola SJ, Wang L, Nemoto N, Tamaki K, Ishida T, Chow LW, Ohuchi N, Sasano H Int J Biol Markers 2014 Sep 30;29(3):e193-203

6. Challenges to effective cancer control in China, India, and Russia Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A Lancet Oncol 2014 Apr;15(5):489-538

7. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I Oncologist 2014 Apr;19(4):348-9

8. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I Oncologist 2014 Apr;19(4):346-7

9. Angiotensin II induces mitochondrial dysfunction and promotes apoptosis via JNK signalling pathway in primary mouse calvaria osteoblast. Li G, Wang M, Hao L, Loo WT, Jin L, Cheung MN, Chow LW, Ng EL. Arch Oral Biol. 2014 May;59(5):513-23. doi: 10.1016/j.archoralbio.2014.02.015. Epub 2014 Mar 4.

10. A pilot study: application of hemoglobin and cortisol levels, and a memory test to evaluate the quality of life of breast cancer patients on chemotherapy. Loo WT, Yip MC, Chow LW, Liu Q, Ng EL, Wang M, Chen J. Int J Biol Markers. 2013 Dec 17;28(4):e348-56. doi: 10.5301/jbm.5000053.

11. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M Breast Cancer Res Treat 2013 Nov;142(1):69-80

Chow L.W.C.

8

12. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Vo Van ML, Bondarenko I Br J Cancer 2013 May 28;108(10):1985-93

13. Comparative evaluation of cytokines in gingival crevicular fluid and saliva of patients with aggressive periodontitis Yue Y, Liu Q, Xu C, Loo WT, Wang M, Wen G, Cheung MN, Bai LJ, Dou YD, Chow LW, Hao L, Tian Y, Li JL, Yip AY, Ng EL Int J Biol Markers 2013 Apr 23;28(1):108-12

14. New developments in breast cancer prognosis: molecularpredictors of treatment response and survival Foo EM, Boost MV, Wong AS, Loo WT, Chow LW, Chow CY Int J Biol Markers 2013 Jun 28;28(2):e131-40

15. Status of oral ulcerative mucositis and biomarkers to monitor posttraumatic

stress disorder effects in breast cancer patients Loo WTY, Liu Q, Yip MCW, Wang M, Chow LWC, Cheung MNB, Yip AYS, Ng ELY Int J Biol Markers 2013 Jun 28;28(2):e168-73

16. Acceptable cardiac safety profile of neoadjuvant 5 -fluorouracil, epirubicin,

cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injury Chow LWC, Loo WTY, Yip AYS, Ng ELY Int J Biol Markers 2013 Apr 23;28(1):e92-9

17. Application of interleukin-1 genes and proteins to monitor the status of chronic

periodontitis Hao L, Li JL, Yue Y, Tian Y, Wang M, Loo WTY, Cheung MNB, Chow LWC, Liu Q, Yip AYS, Ng ELY Int J Biol Markers 2013 Apr 23;28(1):e92-9

18. Application of biomarkers to sentinel lymph node biopsy for the management of

breast cancer Liu Q, Loo WTY, Yip AYS, Chow LWC, Ng ELY, Cheung MNB Chinese Journal of Breast Disease 2013 Mar 21

19. Association of cytokines, high sensitive C-reactive protein, VEGF and beta-

defensin-1 gene polymorphisms and their protein expressions with chronic periodontitis in the Chinese population Tian Y, Li JL, Hao L, Yue Y, Wang M, Loo WTY, Cheung MNB, Chow LWC, Liu Q, Yip AYS, Ng ELY, Chow CY Int J Biol Markers 2013 Apr 23;28(1):e100-e107

20. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed

by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study Chow LWC, Tung SY, Ng TY, Im SA, Lee MH, Yip AYS, Toi M, Glück S Expert Opin Investig Drugs 2013 Mar;22(3):299-307

Chow L.W.C.

9

21. Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow LWC, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF J Clin Oncol 2012 Dec 10

22. Changes of tumor infiltrating lymphocyte subtypes before and after

neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients Chan MSM, Wang L, Felizola SJA, Ueno T, Toi M, Loo WTY, Chow LWC, Suzuki T, Sasano H Int J Biol Markers 2012 Dec 27;27(4):e295-304

23. Evaluation of the psychological and biological changes of patients diagnosed

with benign and malignant breast tumors. Bai LJ, Liu Q, Wang M, Loo WTY, Cheng RWY, Chow LWC, Cheung MNB, Wei KYR, Yip AYS, Ng ELY Int J Biol Markers 2012 Dec 27;27(4):e322-30

24. Correlation of epigenetic change and identification of risk factors for oral

submucous fibrosis Xu C, Zhao J, Loo WT, Hao L, Wang M, Cheung MNB, Dou Y, Yip AYS, Ng ELY, Chow LWC, Liu Q Int J Biol Markers 2012 Dec 27;27(4):e314-21

25. The clinical trials of the Organisation for Oncology and Translational Research

(OOTR) Chow LWC, Toi M Int J Biol Markers 2012 Dec 27;27(4):e353-6

26. Prevention of oncological diseases: primary and secondary prevention

Chow LWC, Yip AYS, Ng ELY Int J Biol Markers 2012 Dec 27;27(4):e337-43

27. Preoperative systemic therapy in locoregional management of early breast

cancer: highlights from the Kyoto Breast Cancer Consensus Conference Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LWC, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T Breast Cancer Res Treat 2012 Dec;136(3):919-26

28. 具抗药性乳腺癌病人的组合性用药治疗方案及其疗效和监察的探讨

Chow LWC, Yip AYS, Liu Q, Loo WTY The 15th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) Educational Book, People’s Medical Publishing House, 243-242

29. Minimally invasive video-assisted thyroidectomy for the early-stage differential

thyroid carcinoma Yu JJ, Bao SL, Yu SL, Zhang DQ, Loo WTY, Chow LWC, Su L, Cui Z, Chen K, Ma LQ, Zhang N, Yu H, Yang WZ, Dong Y, Yip AYS, Ng ELY J of Translational Medicine 2012, 10 Suppl 1: S13

Chow L.W.C.

10

30. Using association rules mining to explore pattern of Chinese medicinal formulae (prescription) in treating and preventing breast cancer recurrence and metastasis He Y, Zheng X, Sit C, Loo WTY, Wang ZY, Xie T, Jia B, Ye QB, Tsui KC, Chow LWC, Chen JP J of Translational Medicine 2012, 10 Suppl 1: S12

31. Mouse model of plasma cell mastitis

Yu JJ, Bao SL, Yu SL, Zhang DQ, Loo WTY, Chow LWC, Su L, Cui Z, Chen K, Ma LQ, Zhang N, Yu H, Yang YZ, Dong Y, Yip AYS, Ng ELY J of Translational Medicine 2012, 10 Suppl 1: S11

32. Clinical application of human β-defensin and CD14 gene polymorphism in

evaluating the status of chronic inflammation Loo WTY, Bai LJ, Fan CB, Yue Y, Dou YD, Wang M, Liang H, Cheung MNB, Chow LWC, Li JL, Tian Y, Qing L J of Translational Medicine 2012, 10 Suppl 1: S9

33. Gene polymorphism and protein of human pro - and anti-inflammatory cytokines

in Chinese healthy subjects and chronic periodontitis patients Loo WTY, Fan CB, Bai LJ, Yue Y, Dou YD, Wang M, Liang H, Cheung MNB, Chow LWC, Li JL, Tian Y, Qing L J of Translational Medicine 2012, 10 Suppl 1: S8

34. Emodin affects ERCC1 expression in breast cancer cells

Fu JM, Zhou J, Shi J, Xie JS, Huang L, Yip AYS, Loo WTY, Chow LWC, Ng ELY J of Translational Medicine 2012, 10 Suppl 1: S7

35. Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph

node metastasis Wei W, Hu H, Tan HS, Chow LWC, Yip AYS, Loo WTY J of Translational Medicine 2012, 10 Suppl 1: S6

36. Comparing serum levels of cardiac biomarkers in cancer patients receiving

chemotherapy and subjects with chronic periodontitis Loo WTY, Yue Y, Fan CB, Bai LJ, Dou YD, Wang M, Liang H, Cheung MNB, Chow LWC, Li J, Tian Y, Qing L J of Translational Medicine 2012, 10 Suppl 1: S5

37. Overexpression of epithelial growth factor receptor (EGFR) predict better

response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer Tang YQ, Zhu L, Li YF, Ji J, Li JF, Yuan F, Wang DB, Chen WG, Huang O, Chen XS, Wu JY, Shen KW, Loo WTY, Chow LWC J of Tranlsational Medicine 2012 10 Suppl 1: S4

38. Decreased Expression of C-erbB-2 and CXCR4 in Breast Cancer after Primary

Chemotherapy Yang SX, Loo WTY, Chow LWC, Yang XH, Zhan Y, Fan LJ, Zhang F, Li C, Wang QL, Xiao HL, Wu JL, Bian XW, Jiang J J of Tranlsational Medicine 2012 10 Suppl 1: S3

39. LMTK3 is implicated in endocrine resistance via multiple signaling pathways

Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LWC, Coombes RC, Sasano H, Shaw JA, Giamas G Oncogene 2012 Aug 6

Chow L.W.C.

11

40. Association of matrix metalloproteinase (MMP)-1, 3, 9, interleukin (IL)-2, 8 and cyclooxygenase (COX)-2 gene polymorphisms with chronic periodontitis in a Chinese population Li GY, Yue Y, Tian Y, Li JL, Wang M, Liang H, Liao PX, Loo WTY, Cheung MNB, Chow LWC Cytokine 2012 Nov;60(2):552-60

41. New therapies in HER2-positive breast cancer: a major step towards a cure of

the disease? Awada A, Bozovic-Spasojevic I, Chow LWC Cancer Treat Rev 2012; 38: 494-504

42. Predictions of the pathological response to neoadjuvant chemotherapy in

patients with primary breast cancer using a data mining technique Takada M, Sugimoto M, Ohno S, Kuroi K, Sato N, Bando H, Masuda N, Iwata H, Kondo M, Sasano H, Chow LWC, Inamoto T, Naito Y, Tomita M, Toi M Breast Cancer Res Treat 2012; 134: 661-670

43. Aromatase inhibitor treatment of breast cancer cells increases the expression of

let-7f, a microRNA targeting CYP19A1 Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS M, Yiu CCP, Loo WTY, Nakamura Y, Akahira JI, Ishida T, Abe K, Hirakawa H, Chow LWC, Suzuki T, Ouchi N, Sasano H J Pathol 2012; 227: 357-366

44. Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis

Wang ZY, Loo WTY, Wang N, Chow LWC, Wang DM, Han F, Zheng X, Chen JP Expert Opin Ther Targets 2012; 16 Suppl 1: S79-89

45. Effects of estrogen depletion on angiogenesis in estrogen -receptor-positive

breast carcinoma--an immunohistochemical study of vasohibin -1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy Chan MS, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo WTY, Chow LWC, Suzuki T, Sasano H Expert Opin Ther Targets 2012; 16 Suppl 1: S69-78

46. Translational research to realize the full potential of novel agents --an

opportunity for vinflunine? Yip AY, Ong EY, Chow LW Expert Opin Drug Saf 2012; 11 Suppl 1: S5-8

47. Increased 5α-reductase type 2 expression in human breast carcinoma following

aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, Wing L, Yiu CC, Chow LWC, Sasano H Horm Cancer 2011; 2: 73-81

48. Bone metabolism and quality-of-life of postmenopausal women with invasive

breast cancer receiving neoadjuvant hormonal therapy: sub -analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Chow LWC, Yip AYS, Chu WP, Loo WT, Toi M J Steroid Biochem Mol Biol 2011; 125(1-2): 112-119

Chow L.W.C.

12

49. Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint Wang ZY, Wang DM, Loo TY, Cheng Y, Chen LL, Shen JG, Yang DP, Chow LWC, Guan XY, Chen JP J Ethnopharmacol 2011; 133: 751-1780

50. Year in review in Asia - The major Asian trials published in 2011 on Breast

Cancer Chow LWC, Yip AYS, Chu WP, Ong EYY The Journal of Japan Society of Clinical Oncology 2011; 46: 1176-1181

51. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy

in patients with early-stage breast cancer Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow LWC, Yip AYS, Glück S Eur J Cancer 2011; 47: 2537-45

52. Bone metabolism and quality-of-life of postmenopausal women with invasive

breast cancer receiving neoadjuvant hormonal therapy: Sub -analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Chow LWC, Yip AYS, Chu WP, Loo WTY, Toi M J Steroid Biochem Mol Biol 2011; 125 (1-2) : 112-9

53. Epigenetic change in E-cadherin and COX-2 to predict chronic periodontitis

Loo WTY, Jin L, Cheung MNB, Wang M, Chow LWC J Transl Med 2010; 8: 110

54. Down-regulation of heat-shock protein 70 (HSP-70) correlated with

responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW C, Toi M, Sasano H Anticancer Res 2010; 30: 3465-3472

55. The Breast Cancer Working Group presentation was divided into three sections:

the epidemiology, pathology and treatment of breast cancer Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno E, Ishiguro H, Bando H Jpn J Clin Oncol 2010; 40 Suppl 1: i13-18

56. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer

patients Loo WTY, Jin LJ, Chow LWC, Cheung MNB, Wang M Expert Opin Investig Drugs 2010; 19 Suppl 1: S91-S100

57. Changes in protein expression after neoadjuvant use of aromatase inhibitors in

primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance Yiu CCP, Sasano H, Ono K, Chow LWC Expert Opin Investig Drugs 2010; 19 Suppl 1: S79-S89

58. Combat against cancer with science and medicine

Chow LWC, Toi M Expert Opin Investig Drugs 2010; 19 Suppl 1: S3-S4

Chow L.W.C.

13

59. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer Chow LWC Expert Opin Investig Drugs 2010; 19 Suppl 1: S13-S17

60. Combination of radiological and biochemical methods to assess bone mineral

density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study Loo WTY, Jin LJ, Cheung MNB, Chow LWC, Wang M Expert Opin Investig Drugs 2010; 19 Suppl 1: S109-S115

61. Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex

pleomorphic adenoma Yang S, Wang HP, Wang XY, Guo LJ, Tang XF, Gao QH, Xuan M, Loo WTY, Chow LWC Expert Opin Investig Drugs 2010; 19 Suppl 1: S101-S108

62. Survival benefits from lapatinib therapy in women with HER2 -overexpressing

breast cancer: a systematic review Yip AYS, Tse LA, Ong EYY, Chow LWC Anticancer Drugs 2010; 21: 487-493

63. Neratinib (HKI-272) 聯合紫杉醇治 ErbB2+ 中國轉移性乳腺癌患者的安全性及有

效性 江澤飛, 徐兵河, 楊俊蘭, Epstein R, Coughlin CM, Freyman A, Zhao Y, 孫強, 李維廉, Kwong A, 周永昌 Linchuang Zhongliuxue Zazhi 2009; 60-61

64. 乳腺癌新輔助化療

Yip AYS, Ong EYY, Yiu CCP, Chow LWC The 12

th Annual Meeting of Chinese Society of Clinical Oncology (CSCO)

Educational Book. Chinese Peking Union Medical College Press 2009; pp525-529

65. Breast cancer management: the way forward

Yip AYS, Chow LWC Hong Kong Med J 2009; 15: 244-245

66. Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase

in human breast carcinoma cells and tissues Loo WTY, Chow LWC, Suzuki T, Ono K, Ishida T, Hirakawa H, Ohuchi N, Sasano H Anticancer Res 2009; 29: 2525-2530

67. Presence of extensive intraductal component in patients undergoing breast

conservative surgery predicts presence of residual disease in subsequent completion mastectomy Yiu CCP, Loo WTY, Lam CK, Chow LWC Chin Med J (Engl) 2009; 122: 900-905

68. Increased expression of annexin I is associated with drug -resistance in

nasopharyngeal carcinoma and other solid tumors Chow BH, Chua DT, Sham JS, Zhang MY, Chow LW C, Bi J, Ma NF, Xie D, Loo WT, Fung JM, Fu L, Guan XY Proteomics Clin Appl 2009; 3: 654-662

69. Latest world development in breast cancer treatment [Article in Chinese]

Yip AYS, Chow LWC Chinese Journal of Breast Disease (Electronic Edition) 2009; 3:215-222

Chow L.W.C.

14

70. Novel therapeutic strategy for breast cancer: mammalian target of rapamycin inhibition Yip AYS, Ong EYY, Chow LWC Expert Opin Drug Discov 2009; 4:457-466

71. Current treatment of locally advanced and metastatic breast cancer in the Asia –

Pacific region: Challenges and limitations Chow LWC, Im YH Asia Pac J Clin Oncol 2009; 4:S14-S23

72. Breast-conserving surgery in Hong Kong Chinese women

Suen D, Chow LWC, Kwong A World J Surg 2008; 32: 2549-2553

73. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast

cancer Chow LWC, Yip AYS, Loo WTY, Lam CK, Toi M J Steroid Biochem Mol Biol 2008; 111: 13-17

74. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally

advanced or metastatic breast cancer Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LWC, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW. J Clin Oncol 2008; 26: 2999-3005

75. Evaluation of neoadjuvant inhibition of aromatase activity and signal

transduction in breast cancer Chow LWC, Yip AYS, Loo WTY, Toi M Cancer Lett 2008; 262: 232-238

76. Vinflunine: Clinical perspectives of an emerging anticancer agent

Yip AYS, Ong EYY, Chow LWC Expert Opin Investig Drugs 2008; 17: 583-591

77. Factors predicting seroma formation after mastectomy for Chinese breast

cancer patients Loo WTY, Chow LWC Indian J Cancer 2007; 44: 99-103

78. PTEN and VEGF: possible predictors for sentinel lymph node mi cro-metastasis in

breast cancer Zhu L, Loo WT, Chow LWC Biomed Pharmacother 2007; 61: 558-561

79. Fructus Schisandrae (Wuweizi) containing compound in modulating human

lymphatic system – a Phase I minimization clinical trial Yip AYS, Loo WTY, Chow LWC Biomed Pharmacother 2007; 61: 588-590

80. Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity

assay achieves better tumor response Lau GI, Loo WT, Chow LWC Biomed Pharmacother 2007; 61: 562-565

Chow L.W.C.

15

81. Effects of Shugansanjie Tang on matrix metalloproteinases 1, 3 and 9 and telomerase reverse transcriptase expression in human breast cells in vitro Loo WTY Chen JP, Chow LWC, Chou JW Biomed Pharmacother 2007; 61: 601-605

82. Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma

tissues and cell lines in vitro Loo WTY, Sasano H, Chow LWC Biomed Pharmacother 2007; 61: 553-557

83. Fructus schisandrae (Wuweizi) containing compound inhibits secretion of HBsAg

and HBeAg in hepatocellular carcinoma cell line. Loo WTY, Cheung MNB, Chow LWC Biomed Pharmacother 2007; 61: 606-610

84. Effects of capecitabine and vinorelbine on cell proliferation, metabolism and

COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. Loo WTY, Sasano H, Chow LWC Biomed Pharmacother 2007; 61: 596-600

85. Pro-inflammatory cytokine, matrix metalloproteinases and TIMP-1 are involved

in wound healing after mastectomy in invasive breast cancer patients. Loo WTY, Sasano H, Chow LWC Biomed Pharmacother 2007; 61: 548-552

86. Chrysomya bezziana: a rare infestation of the breast

Kwong A, Yiu WK, Chow LWC, Wong S Breast J 2007; 13: 297-301

87. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients

with pretreated metastatic breast cancer Chow LWC, Yip AYS, Lang BHH Am J Clin Oncol 2007; 30: 133-138

88. A randomized controlled trial of psychosocial interventions using the

psychophysiological framework for Chinese breast cancer patients Chan CL, Ho RT, Lee PW, Cheng JY, Leung PP, Foo W, Chow LW C, Sham JS, Spiegel D J Psychosoc Oncol 2006; 24: 3-26

89. Breast cancer in limited-resource countries: an overview of the Breast Health

Global Initiative 2005 guidelines Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, Chow LW C, Masood S, Ramsey SD, Carlson RW Breast J 2006; 12 Suppl 1:S3-S15

90. A new predictive and prognostic marker (ATP bioluminescence and positron

emission tomography) in vivo and in vitro for delivering adjuvant treatment plan to invasive breast tumor patient Loo WTY, Tong JM, Cheung MN, Chow LWC Biomed Pharmacother 2006; 60: 285-288

91. Prognostic contribution of the HER-2 oncogene overexpression to the

Nottingham Prognostic Index in breast cancer Suen D, Chow LWC Biomed Pharmacother 2006; 60: 293-297

Chow L.W.C.

16

92. Increase in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients Ueno T, Chow LWC, Toi M Biomed Pharmacother 2006; 60: 277-279

93. Clinical experience with docetaxel for Chinese breast cancer patients:

hematological toxicity profiles Yip AYS, Chow LWC Breast Cancer 2006; 13: 192-196

94. Possible predictive markers related to micro-metastasis in breast cancer

patients Zhu L, Loo WTY, Cheng CW, Chow LWC Oncol Rep 2006; 15:1217-1223

95. Cyclooxygenase-2 and Angiogenesis in Oncology (Editorial) Chow LWC, Toi M Biomed Pharmacother 2005; 59 Suppl 2: S263

96. The efficacy of Paclitaxel on solid tumor analysed by ATP bioluminescence assay

and VEGF expression: A translational research study Loo WTY, Fong JHM, Cheung MNB, Chow LWC Biomed and Pharmacother 2005; 59 Suppl 2: S337-S339

97. The value of bone marrow aspirates culture for detection of bone marrow micrometastasis in breast cancer Loo WTY, Fong JHM, Zhu L, Cheung MNB, Chow LWC Biomed and Pharmacother 2005; 59 Suppl 2: S384-S386

98. Study of COX-2, Ki67 and p53 are used to predict the chances of successful

chemotherapy treatment in breast cancer patients Chow LWC, Loo WTY, Wai CCY, Lui ELH, Zhu L, Toi M Biomed and Pharmacother 2005; 59 Suppl 2: S298-S301

99. DNA Hypermethylation of TIMP3 gene in invasive breast carcinoma affect the outcome of the treatment Lui ELH, Loo WTY, Zhu L, Cheung MNB, Chow LWC Biomed and Pharmacother 2005; 59 Suppl 2: S363-S365

100. Current Directions for COX-2 Inhibition in Breast Cancer

Chow LWC, Toi M Biomed and Pharmacother 2005; 59 Suppl 2: S281-S284

101. Aberrant methylation of cyclooxygenase-2 in breast cancer patients

Chow LWC, Zhu L, Loo TY, Lui ELH Biomed and Pharmacother 2005; 59 Suppl 2: S264-S267

102. Circulating tumor cells in patients with breast cancer: predictor of micro-

metastasis in bone marrow but not in sentinel lymph nodes Zhu L, Loo TYW, Chow LWC Biomed and Pharmacother 2005; 59 Suppl 2: S355-S358

103. Serum lipid profiles in patients receiving endocrine treatment for breast cancer

- the results from the Celecoxib Anti-Aromatase Neuoadjuvant (CAAN)Trial Chow LWC, Cheng CWN, Wong JLN, Toi M Biomed and Pharmacother 2005; 59 Suppl 2: S302-S305

Chow L.W.C.

17

104. Trastuzumab: updates and future issues Toi M, Horiguchi K, Bando H, Saji S, Chow LW C Cancer Chemother Pharmacol 2005; 56 Suppl 1: S94-S99

105. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13

amplification and DNA methylation in breast cancer Cheng CK, Chow LWC, Loo WTY, Chan TK, Chan V Cancer Res 2005; 65: 8646-8654

106. Phase II study on an “all oral” regimen of capecitabine, idarubicin and

cyclophosphamide of metastatic breast cancer: safety, efficacy and quality of life Tong DKH, Cheng CW, Chan SC, Wong LNJ, Chow LWC Oncology 2005; 68: 520-525

107. Association between body mass index and the risk of formation of breast cancer

in Chinese women Chow LWC, Lui KL, Chan JC, Chan TC, Ho PK, Lee WY, Leung LH, Sy WM, Yeung CC, Yung AK Asian J Surg 2005; 28: 179-184

108. The Chinese Medical Interview Satisfaction Scale -revised (C-MISS-R):

development and validation Lam WW, Fielding R, Chow LW, Chan M, Leung GM, Ho EY. Qual Life Res 2005; 14:1187-1192

109. Translational Research in Breast Cancer

Toi M, Takebayashi Y, Chow LWC Breast Cancer 2005; 12: 86-90

110. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in

cancer biology and treatment. Toi M, Rahman MA, Bando H, Chow LWC Lancet Oncol 2005; 6:158-166

111. Gambling with your life: The process of breast cancer treatment decision

making in Chinese women Lam WW, Fielding R, Chan M, Chow L, Or A Psychooncology 2005; 14: 1-15

112. Arimidex inhibition on proliferation of human breast solid tumors measured by

ATP bioluminescence Tse EYT, Chow LWC, Loo WTY, Cheng CW Life Sci 2004; 76: 827-834

113. Production of matrix metalloproteinase in specific subpopulations of human -

patient breast cancer invading in 3-dimensional culture system Loo TYW, Chow LWC, Cheung MB Life Sci 2004; 76 :743-752

114. Novel insights in clinical trials with preoperative systemic therapy for primary

breast cancer Toi M, Bando H, Chow LWC Biomed Pharmacother 2004; 58: 531-535

115. The inhibitory effects of a herbal formula comprising ginseng and carthamus tinctorius on breast cancer Loo WTY, Chow LWC, Sham JST Life Sci 2004; 76: 191-200

Chow L.W.C.

18

116. Sentinel lymph node biopsy – here to stay (Editorial)

Chow LWC Asian J Surg 2004; 27: 255

117. Sentinel lymph node biopsy or detection of micrometastasis in bone marrow:

Which might be an alternative to axillary local lymph node dissection in breast cancer patients? Zhu L, Lam CK, Chow LWC Asian J Surg 2004; 27: 279-283

118. Radix bupleuri containing compound (KY88 liver -livo) induces apoptosis and

production of interleukin-4 and tumor necrosis factor-α in liver cancer cells in vitro Chow LWC, Loo WTY, Sham JST, Cheung MNB Am J Chin Med 2004; 32: 185-193

119. Her2/neu expression predicts the response to antiaAromatase neoadjuvant

therapy in advanced breast cancer: subgroup analysis from CAAN Trial Zhu L, Chow LWC, Loo WTY, Guan XY, Toi M Clin Cancer Res 2004; 10: 4639-4644

120. Sentinel lymph node technique for breast cancer: Radiation safety issues for

radioguided surgery Law M, Chow LWC, Lam CK, Kwong A, Yiu CCP Semin Oncol 2004; 31:298-303

121. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast

cancer: preliminary report Chow LWC, Wong LNJ, Toi M J Steroid Biochem Mol Biol 2003; 86:443-447

122. Patient effective dose of sentinel lymph node lymphoscintigraphy in breast

cancer: a study using female humanoid phantom and thermoluminescent dosimeters Law M, Cheng KC, Wu PM, Ho WY, Chow LWC Br J Radiol 2003; 76: 818-823

123. Pattern of alternative medicine usage among the Chinese breast cancer

patients: implication for service integration Abdullah ASM, Lau Y, Chow LWC Am J Chin Med 2003; 31: 649-658

124. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer

patients: clinical implications Hu XC, Wong I, Chow LWC Oncol Rep 2003; 10: 1811-1815

125. Participation and satisfaction with surgical treatment decision -making in breast

cancer among Chinese women Lam W, Fielding R, Chan M, Chow L, Ho E Breast Cancer Res Treat 2003; 80: 171-180

126. Prospective pilot study of the preoperative use of celecoxib and FEC for locally

advanced breast cancer Chow LWC, Toi M Breast 2003; 12 Suppl 1:S40

Chow L.W.C.

19

127. The study of cytokine dynamics at the operation site after mastectomy Chow LWC, Loo WTY, Yuen KY, Cheng C Wound Repair Regen 2003; 11: 326-330

128. The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on

apoptotic marker (CPP-32), pro-apoptotic protein (p21WAF-1) and anti-apoptotic protein (bcl-2) in breast cancer cells Chow LWC, Loo TYW Breast Cancer Res Treat 2003; 80: 239-244

129. A rat cell line derived from DMBA-induced mammary carcinoma

Chow LWC, Cheung MNB, Loo WTY, Guan XY Life Sci 2003; 73: 27-40

130. Polysaccharide peptide mediates apoptosis by up-regulating p21 gene and

down-regulating cyclin D1 gene Chow LWC, Lo CS, Loo WT, Hu XC, Sham JST Am J Chin Med 2003; 31: 1-9

131. Breast sentinel lymph node biopsy using radioisotope injection: is one -day

better than two-day protocol? Chok SH, Chow LWC, Wong KH, Cheng KC, Ho WY Am Surg 2003; 69: 358-361

132. Surgery-related shedding of breast cancer cells as determined by RT -PCR assay

Hu XC, Loo TY, Chow LWC J Surg Oncol 2003; 82: 228-232

133. Immunomagnetic tumor cell enrichment is promising in detecting circulating

breast cancer cells Hu XC, Wang Y, Shi DR, Loo TY, Chow LWC Oncology 2003; 64: 160-165

134. Cytokine production by human lymphocytes stimulated by a herbal compound

containing Bupleurum (KY88 LIVER LIVO) Chow LWC, Loo TYW, Sham JST Acta Pharmacol Sinica 2003; 24: 140-144

135. Application of image-guided biopsy for impalpable breast lesions in Chinese

women Tsang FHF, Lo JJ, Wong JLN, Lee FCW, Chow LWC ANZ J Surg 2003; 73: 23-25

136. Comparison of TPS with CEA and CA 15.3 in follow -up of Chinese breast cancer

patients Hu XC, Day W, Jones B, Loo TY, Chow LWC Anticancer Res 2002; 22: 1865-1868

137. E-cadherin promoter methylation can regulate its expression in invasive ductal

breast cancer tissue in Chinese woman Hu XC, Loo WTY, Chow LWC Life Sci 2002; 71: 1397-1404

138. Early introduction of clinical skills teaching in a medical curriculum —factors

affecting students' learning Lam TP, Irwin M, Chow LWC, Chan P Med Educ 2002; 36: 233-240

Chow L.W.C.

20

139. Effects of a herbal compound containing bupleurum on human lymphocytes Chow LWC, Loo WTY, Sham JST Hong Kong Med J 2001; 7: 408-413

140. Clinical value of serum tumor markers in breast cancer patients

Hu XC, Loo WTY, Chow LWC Chin Med J 2001; 114: 6

141. Sentinel lymph node biopsy for breast cancer

Ng KKC, Chow LWC Ann Coll Surg HK 2001; 5: 116-120

142. Neoadjuvant chemotherapy for Chinese women with locally advanced breast

cancer Chow LWC, Day W, Ng KCK Am Surg 2001; 67: 412-416

143. Detection of circulating breast cancer cells with multiple -marker RT-PCR assay

Hu XC, Chow LWC Anticancer Res 2001; 21: 421-424

144. The use of focus group interviews in Asian medical education evaluative

research Lam TP, Irwin M, Chow LWC, Chan P Med Educ 2001; 35: 510-513

145. The impact of postoperative nausea and vomiting on the practice of day surgery

for Chinese women with breast diseases Choi HK, Chow LWC, Goh LC, Tsui SL, Lee F Ambul Surg 2001; 9: 29-32

146. Clarithromycin attenuates mastectomy-induced acute inflammatory response

Chow LWC, Yuen KY, Woo PCY, Wei WI Clin Diagn Lab Immunol 2000; 7: 925-931

147. Fine needle aspiration may shed breast cells into peripheral blood as

determined by RT-PCR Hu XC, Chow LWC Oncology 2000; 59: 217-222

148. Hormonal receptor determination of 1,052 Chinese breast cancers

Chow LWC, Ho P J Surg Oncol 2000; 75: 172-175

149. Practice of breast self-examination among high risk Chinese women in Hong

Kong Ng KKC, Fung SY, Chow LWC Chin Med J 2000; 113: 1110-1113

150. Detection of circulating breast cancer cells by reverse transcriptase polymerase

chain reaction (RT-PCR) Hu XC, Chow LWC Eur J Surg Oncol 2000; 26: 530-535

151. MR appearance of metastatic melanotic melanoma in the breast

Ho LWC, Wong KP, Chan JH, Chow LWC, Leung EYF, Leong L Clin Radiol 2000; 55: 572-573

Chow L.W.C.

21

152. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia Ting ACW, Chow LWC, Leung YF Am Surg 2000; 66: 38-40

153. Acute myeloid leukemia relapsing as gynecomastia

Au WY, Ma ESK, Kwong YL, Lie AKW, Shek WH, Chow LWC, Liang R Leuk Lymphoma 1999; 36: 191-194

154. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian

cancer Khoo US, Ozcelik H, Cheung ANY, Chow LWC, Ngan HYS, Au GKH, Man EPS, Chan V, Ng WF, Poon CSP, Leung YF, Loong F, Ip P, Chan GSW, Andrulis IL, Ho FCS Oncogene 1999; 18: 4643-4646

155. Clarithromycin attenuates the inflammatory response induced by surgical

trauma in a guinea pig model Woo PCY, Chow LWC, Ma ESK, Yuen KY Pharmacol Res 1999; 39: 49-54

156. Bleeding peptic ulcer: an evolving role for surgical intervention

Branicki FJ, Ting ACW, Gertsch P, Tuen HH, Chu KM, Chow LWC, Wong J J Gastroenterol Hepatol 1998; 13 Suppl: S227-S231

157. Comparison of antiemetic efficacy of granisetron and ondansetron in Chinese

patients receiving chemotherapy for breast cancer: a randomised crossover study Poon RTP, Chow LWC Br J Cancer 1998; 77: 1683-1685

158. Bleeding peptic ulcer in the very elderly: risk factors for re-bleeding and

mortality Chow LWC, Gertsch P, Poon RTP, Branicki FJ Br J Surg 1998; 85: 121-124

159. Lymphoma of the breast in Hong Kong Chinese

Au WY, Chan ACL, Chow LWC, Liang R Haem Oncol 1997; 15: 33-38

160. p53 expression in recurrent nodal metastases from nasopharyngeal carcinoma

Chow LWC, Khoo US, Yuen APW, Wei WI Eur J Surg Oncol 1997; 23: 415-418

161. Wide margin excision and brachytherapy for post -radiation breast cancer

recurrence Chow LWC, Cheng ACK, Lam LK, Ho CM, Au GKH J Surg Oncol 1997; 65: 55-56

162. Breast conservative therapy for invasive breast cancer in Hong Kong: factors

affecting recurrence and survival in Chinese women Chow LWC, Au GKH, Poon RTP Aust NZ J Surg 1997; 67: 94-97

163. Immunohistochemical analysis of antimeatstatic gene NM23 in human breast

carcinoma Khoo US, Loong F, Chow LWC, Cheung KL, Ng WF, Cheung ANY Pathol Int 1997; 47: A7

Chow L.W.C.

22

164. Bleeding peptic ulcer in Hong Kong: stratification of risk factors in 1441 patients Chow LWC, Ting ACW, Gertsch P, Branicki FJ Asian J Surg 1997; 20: 279-282

165. Current status of breast cancer in Hong Kong

Chow LWC, Ting ACW, Cheung KL, Au GKH, Alargaratnam TT Chin Med J 1997; 110: 474-478

166. Thoracoscopic vagotomy for the treatment of recurrent peptic ulcer after

surgery Poon RTP, Chow LWC, Lim BH, Gertsch P Aust NZ J Surg 1997; 67: 177-180

167. Laparoscopic Taylor’s procedure in Chinese patients

Gertsch P, Chow LWC, Lim BH Gastrointest Endosc 1996; 43: 243-247

168. Long term survival time after gastrectomy for advanced bleeding or perforated

gastric carcinoma Gertsch P, Chow LWC, Yuen ST, Chau KY, Lauder IJ Eur J Surg 1996; 162: 723-727

169. Update article – conservative breast surgery for breast cancer

Poon RTP, Chow LWC, Au GKH Hong Kong Practitioner 1996; 18: 68-72

170. Intrapancreatic avulsion of the common bile duct after blunt abdominal trauma

Chow LWC, Gertsch P, Cheung KL, Leung SYL Eur J Surg 1996; 162: 519-521

171. Atrophy of hand muscles and gastric cancer – coincidence or a paraneoplastic

manifestation Chow LWC South Med J 1995; 88: 961-963

172. Gastric cancer with synchronous liver metastasis: palliative gastrectomy or not?

Chow LWC, Lim BH, Leung SYL, Branicki FJ, Gertsch P Aust NZ J Surg 1995; 65: 719-723

173. Pyogenic hepatic abscess and carcinoma of colon

Chow LWC, Lo CY, Ng WK, Gertsch P Illustrated Case Reports in Gastroenterol 1995; 2: 5-10

174. A pregnant woman with a rapidly growing breast lump

Khoo US, Chow LWC, Ho LWC, Tam R, Alagaratnam TT, Cheung ANY Hong Kong Med J 1995; 1: 253-257

175. Free perforation of gastric carcinoma: results of surgical treatment

Gertsch P, Yip SKH, Chow LWC, Lauder IJ Arch Surg 1995; 130: 177-181

176. Efficacy of leucocyte count and neutrophil percentage in the clinical diagnosis

of acute appendicitis Chow LWC, Loh TKS, Ong CL, Png DJC Asian J Surg 1994; 17: 49-52

Chow L.W.C.

23

177. Retroperitoneal perforation complicating through-the-scope pyloric dilatation Chow LWC, Ong CL Gastrointest Endosc 1994; 40: 122-123

178. Fournier’s gangrene

Chow LWC, Ong CL, Png DJC, Loh TKS, Rajagopalan R Br J Clin Pract 1993; 47: 277-278

179. Gallbladder empyema – another good reason for early cholecystectomy

Chow WC, Ong CL, Png DJC, Rauff A J R Coll Surg Edinb 1993; 38: 213-215

180. Massive per rectal bleeding from an ulceration in a jejunal diverticulum

Chow LWC, Ong CL, Png DJC J Clin Gastroenterol 1993; 17: 85-86

181. Role of sequential leucocyte counts and c-reactive protein measurements in

acute appendicitis Chow LWC, Loh TKS, Ong CL Brit J Surg 1993; 80: 673

182. Necrotizing fasciitis revisited

Chow LWC, Ong CL, Png DJC, Loh TKS, Rajagopalan R Contemp Surg 1993; 42: 181-184

183. Percutaneous fine needle aspiration cytology for solid pulmonary lesions

Chow WC, Yip WC, Cheng CS, Lam HS, Chan NK, Gwi E, Nandi PL Asian J Surg 1993; 16: 67-70

184. Technical modification to laparoscopic appendectomy

Goh P, Tekant Y, Kum CK, Chow L, Ngoi SS Dis Colon and Rectum 1992; 35: 999-1000

185. Intracranial meningioma with metastatic breast carcinoma

Chow WC, Ho KH, Fong CM Ann Oncol 1992; 3: 409-410

186. Mirrzi syndrome with cholecystocholedochal fistula: preoperative diagnosis and

management Yip WC, Chow WC, Chan J, Lam KH Surgery 1992; 111: 335-338

187. Tension pneumoperitoneum after colonoscopic polypectomy

Yip WC, Chow WC, Chan J Endoscopy 1991; 23: 241

188. Plea for selective operative cholangiography

Yip WC, Ng WS, Chow WC, Choi TK, Lam KH J R Coll Surg Edinb 1991; 36: 21-24

189. Interpostion drafting for femoral venous injury

Nandi PL, Chow WC, Yip WC Asian J Surg 1990; 13: 222-225

190. Removal of intrahepatic stone

Ng SK, Yip WC, Chow WC, Choi TK Gastrointest Endosc 1990; 36: 402-404

Chow L.W.C.

24

Book Chapter

1. Chow LWC. Combination Anti-aromatase therapy. In “Anti-Aromatase therapy for Breast Cancer - New Developments”. Sasano H and Toi M Eds. Ch5; pp227-235

2. 周永昌, 鲁慶榮. 實用乳腺病學. In “国际乳腺癌临床研究现状及展望 Practice of Breast Diseases”. 崔维奇, 雷秋模, 左文迷, 张凤春, 漆幼珊, 彭成华. Ch1; pp5-24

Patent

A mouse cell line derived from human malignant cystosarcoma phylloides

Prizes

1. 第七届全国乳腺癌重庆论坛, Chongqing, China, December 21-23, 2012 (中华医学会金显宅乳腺癌研究纪念奖 / Kim Hyun-Jib Breast Cancer Research Memorial Award)

2. Cyclooxygenase-2: Possible Predictor Related to Micro-metastasis in Breast

Cancer Patients Zhu L, Chow LWC 1st Annual Scientific Conference, Organisation for Oncology and Translational Research, October 2004, Hong Kong (Young Investigator Award)

3. The Correlation of Tumor Markers CEA and CA15.3 with the extent of breast

cancer using 18-flouro-2-deoxy-D-glucose positron emission tomography (

18FDG-PET)

Kwong AK, Cheng CW, Yeung D, Lam CK, Chow LWC Annual Congress, Asian Surgical Association, Kota Kinabalu, December 2003 (1st prize award for poster)

4. The use of Nottingham Prognostic index and c -erb-B2 status as prognostic indicators of Chinese breast cancer Kwong A, Chow LWC 1st Roche Asia Oncology Forum, Shanghai, China, September 2002 (1st prize award)

Research Supervision Experience

1. Supervision of Ph.D. Student Dr XC Hu: Detection of micrometastasis of breast cancer by RT-PCR

2. Supervision of M MedSci Student

Dr Chung Pui Yi, Rebecca: Breast care module

3. Supervision of MPhil Student

Dr Zhu Li: Detection of bone micrometastasis from breast cancer

4. Supervision of MMedSci Student

Mr Eric Lui: TBC

Examiners for Postgraduate Examinations

1. Internal Examiner for Dr K.C. Ng, Ph D Candidate, The University of Hong Kong, 2004 Local and systemic effects of hepatic radiofrequency ablation in animal models

Chow L.W.C.

25

2. Additional Examiner for Professor ST Fan, PhD Candidate, The University of Hong Kong, 2003 Adult-to-adult live donor liver transplantation using right lobe graft

3. Internal Examiner for Ms Leung Wai Ching Wa, Gina, PhD candidate, The

University of Hong Kong, 2002 The influence of flutamide, tamoxifen and dietary fat on hormone-induced mammary carcinogenesis

4. Internal Examiner for Ms Mable Wu, MMedSci candidate, The University of

Hong Kong, 2002

5. Internal Examiner for Mr Xi Chun Hu, PhD candidate, The University of Hong

Kong, 2001 Study on the Use of Potential Prognostic Parameters in Breast Cancer Patients

International Research Collaboration

Project Tumour invasion and histoculture drug response assay (HDRA)

Collaborator Dr Robert M. Hoffman President, AntiCancer Inc, San Diego and Professor, Department of Surgery, University of California, San Diego

Project Changes in angiogenesis markers after neoadjuvant treatment

of breast cancer

Collaborator Dr Masakazu Toi Director, Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

Research/Professional Grants Awarded

1. Chemosensitivity Testing Service for Selection of Chemotherapy in Breast Cancer Patients (Project no.: 204217)

Source: SK Yee Medical Foundation Grant 2004

Amount: HK$1,158,753.20

2. The effects of psychosocial intervention on the psychosocial and

neuroendocrine outcomes: a prospective 3-group randomised trial with Chinese breast cancer patients (as co-investigator)

Source: RGC Competitive Earmarked Research Grant Award 2003 -2004

Amount: HK$282,100

3. Radioguided Surgery and Breast Cancer Management Course and Seminars

(Ref: 2002-2-27)

Source: Professional Services Development and Assistance Scheme 2003

Duration: 2002-2004

Amount:

HK$249,000

Status: stat

Project completed

4. Methylation changes during longitudinal follow-up of breast cancer patients

Source: CRCG Research Grant

Duration: September 2002 to April 2004

Amount:

HK$120,000 Status:

stat Project completed

Chow L.W.C.

26

5. Collaborative Laboratory Research on KY88 Liver Livo

Source: Innovation and Technology Fund; University -Industry Collaboration Programme

Duration: April 2000 to March 2002

Amount:

HK$ 670,000

Status: stat

Project completed

Publications

i. Chow LWC, Loo WTY, Sham JST. Effects of Bupleurum containing herbal compound on human lymphocytes. Hong Kong Med J. 2001; 7: 408-413

ii. Chow LWC, Loo WTY, Sham JST, et al. Radix bupleuri containing compound (KY88 liver-livo) induces apoptosis and production of interleukin-4 and tumor necrosis factor-α in liver cancer cells in vitro. Am J Chin Med. 2004; 32: 185-193

iii. Chow WCL, Loo TY, Sham STJ Cytokine production by human lymphocytes stimulated by a herbal compound containing Bupleurum (KY88 LIVER LIVO). Acta Pharmacol Sinica 2003; 24: 140-144

Donations

A total of HK$2,500,000 was donated from personal/company accounts to the Division of Breast Surgery for research purposes

Applied/Translational Research

Co-investigator of International Clinical Trials (as listed in Clinical Trials Centre of HKU)

Protocol HERA: A randomised three-arm multi-centre comparison of 1 year and 2 years of Herceptin® versus no Herceptin® in women with HER2 -positive primary breast cancer who have completed adjuvant chemotherapy

Protocol No.: BIG01-01/BO16348B, Sponsored by Roche

Remarks: Completed patient enrolment

Protocol A multicenter phase III randomized trial comparing Docetaxel in

combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide followed by Docetaxel (ACT) as adjuvant treatment of operable breast cancer HER2/neu negative patients with positive axillary lymph nodes. BCIRG 005

Protocol No.: BCIRG 005, Sponsored by Adventis

Remarks: Completed patient enrolment

Protocol Multicenter Phase III Randomized Trial Comparing Doxorubicin and

Cyclophosphamide followed by Docetaxel (ACT) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (Herceptin®) (ACTH) and with Docetaxel, Carboplatin and Trastuzumab (TCH) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer containing the HER2 Alteration

Protocol No.: BCIRG 006, Sponsored by Adventis

Remarks: Completed patient enrolment

Protocol Amonafide: Individual phenotype-adjusted chemotherapy for women with

metastatic breast cancer who have progressed despite prior chemotherapy

Protocol No.: 0001A1-200-GL, Sponsored by Xanthus, CRO: Orion

Remarks: Completed patient enrolment

Protocol An Open-Label, Randomized, Multicenter Study to Evaluate the Use of

Zoledronic Acid in the Prevention of Cancer Treatment -Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+Breast Cancer Receiving Letrozole as Adjuvant Therapy

Protocol No.: CFEM345D2405, Sponsored by Novartis

Chow L.W.C.

27

Protocol A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First -Line Monotherapy in Patients with Advanced or Metastatic Breast Cancer.

Protocol No.: EGF 20009, Sponsored by GSK Remarks: Completed patient enrolment

Principal Investigator of International Clinical Trials

1. Prospective Randomized Celebrex Anti -Aromatase Neoadjuvant (CAAN) trial on Locally Advanced Breast Cancer

2. Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy

in Patients with Invasive Breast Cancer

3. Evaluation of the Neoadjuvant Inhibition of Armoatase Activity and Signal

Transduction in Breast Cancer: The Femara/Glivec Study

4. Randomized Trial of Docetaxel (T) with or without Capecitabine (X) as

Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC)

Editorial Board Membership

1. Member, International Editorial Committee, The Journal of Breast Cancer

2. Member, Editorial Board, Chinese Journal of Surgical Therapy

3. Member, Editorial Board, BMJ (Chinese)

4. Member, Editorial Board, Update in Breast Cancer Therapy

5. Guest Editor, Breast Cancer Symposium

Asian Journal of Surgery

6. Member of Editorial Board, The Chinese Journal of Surgical Oncology

February 2004 – present

7. Corresponding Editor, Chinese Medical Journal (Beijing)

Chinese Medical Association, China, June 2000 to present

8. Editor, Faculty Newsletter

Faculty of Medicine, University of Hong Kong, April 2000 to present

Guest Editor

Symposium on Sentinel Lymph Node Biopsy, October Issue, 2004, Asian Journal of Surgery

Journal Reviewer

1. Annals of Hong Kong College of Surgeons

2. Hong Kong Medical Journal

3. Asian Journal of Surgery

Chow L.W.C.

28

4. Journal of Pharmacology and Experimental Therapeutics

5. Clinical Cancer Research

6. Journal of Clinical Chemistry

7. International Immunopharmacology

8. Journal Biologia, Bratislava

9. Journal of Breast Cancer (External Peer Reviewer) 10. Chinese Journal of Traditional and Western Medicine (Executive Chief

Editor)

11. Cancer Epidemiology, Biomarkers & Prevention (External Reviewer) 12. Journal of Cancer Research and Therapeutics (External Reviewer) 13. Annals of Oncology (External Reviewer)

Invited / Plenary Lectures

1. 乳腺癌手术：实践与研究 2013 年西南医院乳腺外科学术年会, Chongqing, China, December 14, 2013

2. 乳腺癌的治疗 第一届深港肿瘤防治论坛暨深圳市抗癌协会学术年会 , Shenzhen, China, December 7, 2013

3. 乳腺癌轉化研究之晚期乳腺癌復發、轉移治療方法 第五屆江西乳腺疾病高層論壇, Jiangxi, China, November 22-23, 2013

4. Refining Clinical Approach to HER2-Positive Early Breast Cancer Roche Korea Breast Cancer Forum, Gwangju, Korea, October 26-27, 2013

5. The role of mTOR inhibitors in the management of advanced breast cancer Philippines Breast Cancer Society Meeting, Manila, Philippines, October 23 -24, 2013

6. Understanding Intratumor Heterogeneity 第十六届全国临床肿瘤学大会暨 2013 年 CSCO 学术年会 , Xiamen, China, September 25-29, 2013

7. 乳腺癌肿瘤异质性 第五届全国乳腺微创外科大会, Chongqing, China, September 13-16, 2013

8. 早期乳腺癌的分子诊断与治疗 中国乳腺病论坛, Beijing, China, September 13-15, 2013

9. 香港年轻乳腺癌治疗现状 中国年轻乳腺癌南北高峰论坛, Wuyishan, China, August 10-11, 2013

10. 复发转移乳腺癌的治疗进展 甲状腺、乳腺疾病诊治新视觉学习班, Shenzhen, China, August 2, 2013

11. New Strategies for an Evolving Disease Breast Cancer Tour, Beijing & Shanghai, June 22-23, 2013

Chow L.W.C.

29

12. 乳腺癌个体化治疗的发展及挑战 第二届海峡乳腺论坛暨第四届福建省乳腺论坛 , Xiamen, China, June 15-16, 2013

13. How could we select patients for IORT after Breast Conservation Surgery IORT in Breast Cancer Symposium, Hong Kong, China, May 27, 2013

14. The Feasibility of IORT for Asian Breast Cancer Patients with Median Size

Breasts (Indications of IORT in Asian Breast Cancer Patients) New Frontier in Breast Cancer Surgery - Trans-Asia Symposium of Intra-Operative Radiotherapy & Surgical Techniques, Taipei, Taiwan, May 25, 2013

15. Achieving Best Outcome of Conserving Breast Surgery

New Frontier in Breast Cancer Surgery - Trans-Asia Symposium of Intra-Operative Radiotherapy & Surgical Techniques, Taipei, Taiwan, May 25, 2013

16. HER2 陽性乳腺癌治療新進展

Macau Oncology Association Exchange Symposium, Macau, China, May 18, 2013

17. 乳腺癌治疗新突破

第 5 届广东乳腺病研讨会, Guangzhou, China, May 17-18, 2013

18. A multimodality approach to neoadjuvant therapy for breast cancer

The 9th Annual Conference of the Organisation for Oncology and Translational Research (OOTR) in conjunction with The Asian Oncology Summit (AOS) 2013, Bangkok, Thailand, March 22-24, 2013

19. Racial differences in breast cancer treatment

The 9th Annual Conference of the Organisation for Oncology and Translational Research (OOTR) in conjunction with The Asian Oncology Summit (AOS) 2013, Bangkok, Thailand, March 22-24, 2013

20. 从临床获益向乳腺癌个体化治疗的转变

The 5th Harbin Breast Cancer Forum, Harbin, China, January 5, 2013

21. 乳腺癌手术治疗之最新进展

第七届全国乳腺癌重庆论坛, Chongqing, China, December 21-23, 2012

22. 崭新靶向药物治疗耐药性乳腺癌

第五届粤港澳肿瘤大会暨第九届全国肿瘤综合治疗新进班 , Zhongshan, China, October 13-14, 2012

23. 乳腺癌外科的微创理念与进展

第三屆中國腫瘤外科微創學術研討會, Yinchuna, China, September 28-30, 2012

24. What is Adequate Margin in Chinese Small or Medium Size Breast

2012 Taipei International Breast Cancer Symposium (TIBCS), Taipei, Taiwan, September 21-23, 2012

25. 具抗药性乳腺癌病人的组合性用药治疗方案及其疗效和监察的探讨

The 15th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Beijing, China, September 19-23, 2012

26. 探讨具抗药性乳腺癌病人临床组合性药物治疗的新方案及疗效的监察

江西南昌国际论坛, Nanchang, China, September 7-9, 2012

27. Basal Subtype Breast Cancer - Therapeutic Implication

10th Asian Breast Diseases Association (ABDA) Teaching Course and Workshop, Hong Kong, June 22-24, 2012

28. Personalized Medicine in Breast Cancer

10th International Conference of Asian Clinical Oncology Society (ACOS), Seoul, Korea, June 13-15, 2012

Chow L.W.C.

30

29. Prevention of oncological diseases The 8

th Annual Conference of Organisation for Oncology and Translational

Research (OOTR), Kyoto, Japan, April 20-21, 2012

30. Research into new targeting agents

Asian Oncology Summit (AOS) 2012, Singapore, April 13-15, 2012

31. Prospective strategies to treat drug resistant cancers

Asian Oncology Summit (AOS) 2012, Singapore, April 13-15, 2012

32. 乳腺癌的术前治疗策略

Chang Gung Memorial Hospital Breast Cancer Conference 2011, Taipei, Taiwan, December 17, 2011

33. Private Health Care Sector as an Alternative Study Site Provider

Clinical Trial Magnifier Conference 2011, Taipei, Taiwan, November 18-20, 2011

34. Current Status and Clinical Development of BC Stream

APECHO-LEAD Summit, Seoul, Korea, October 28-29, 2011

35. Year in review in Asia

49th Annual Meeting of the Japanese Society of Clinical Oncology (JSCO), Aichi, Japan, October 27-29, 2011

36. 乳腺癌的术前治疗策略

恶性肿瘤诊治新进展专题讨论会, Shenzhen, China, October 2 - 5, 2011

37. 乳腺癌新辅助治疗与耐药机制的探索

第四届全国乳腺微创治疗研讨会, Chongqing, China, September 23 – 26, 2011

38. 个体化新辅助治疗和辅助手段的应用

The 14th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Xiamen, China, September 14 – 18, 2011

39. Breast Cancer Therapy

9th Asia Pacific Oncology Summit (APOS), Bangkok, Thailand, August 19 – 20, 2011

40. Personalizing Neoadjuvant Therapy and Applications Toward Adjuvant

Approaches Asian Pacific Oncology Conference (APOC), Nanjing, China, July 15 – 17, 2011

41. 内分泌药物治疗对绝经后乳腺癌病人骨质疏松的影响

中国抗癌协会乳腺癌诊治指南与规范（2011 版）全国巡讲（江西站）暨第三届江西乳腺疾病高层论坛, Nanchang, China, July 2 – 3, 2011

42. Optimal use and future perspective of neoadjuvant therapy in breast cancer

Kyoto Breast Cancer Consensus Conference (KBCCC), Kyoto, Japan, April 14 – 16, 2011

43. Expectations with Expertise: Practical Management Forum

Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 – 10, 2011

44. Application of biomarkers to sentinel lymph node biopsy for the management

of breast cancer Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 – 10, 2011

45. Hormone therapy for metastatic breast cancer

Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 - 10 2011

46. Breast Reconstruction after Breast Conservative Surgery with Autologous

Tissue 3rd International Oncoplastic Breast Surgery Symposium, Tokyo, Japan, November 25 – 26, 2010

Chow L.W.C.

31

47. 初期乳癌的診斷方法

第二届粵港澳檢驗醫學學術大會檢驗新進展國際研討會 , Macau, November 5 -7, 2010

48. Inter-disciplinary Expert Panel Discussion II N.O.T.E.S. - Chairman 2nd World (20th Chinese) Endoscopy Doctors Conference & 2nd Macau-Hong Kong Surgical Scientific Meeting, Macau, October 29 – November 1, 2010

49. 國際乳腺癌臨床研究現狀和展望 第六届全国乳腺癌重庆论坛, Chongqing, China, September 24 – 26, 2010

50. 转化性研究与个人化治疗

The 13th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Beijing, China, September 16 – 19, 2010

51. Update Adjuvant Chemotherapy Focus on Triple -Negative Breast Cancer

Taipei International Breast Cancer Symposium, Taiwan, September 3 – 5, 2010

52. Global and Asian consensus in breast cancer managements – case presenter

9th International Conference of The Asian Clinical Oncology Society (ACOS), Gifu, Japan, August 25 – 27, 2010

53. Do we need to perform lymphadenectomy if sentinel node is positive?

UICC World Cancer Congress, Shenzhen, China, August 18 – 21, 2010

54. Investigator Breast Cancer Trial Network in China and Asia

Clinical Trial Magnifier 2009 Conference (CTC), Hong Kong, November 13-15, 2009

55. General Situation of Breast Cancer and Screening in Hong Kong and Macao

The Second Asia Pacific Health Symposium, Tainan, Taiwan, November 8, 2009

56. 乳腺癌 HER2 信号传导研究进展

The 12th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Xiamen, China, October 2009

57. 乳腺癌新辅助化疗

The 12th

Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Xiamen, China, October 2009

58. Towards Anthracycline-free in Adjuvant Setting

Global Breast Cancer Conference 2009 with the 7th

Biennial Meeting of the Asian Breast Cancer Society (ABCS), Seoul, Korea, October 2009

59. Introduction of Breast Cancer

Breast Cancer Nurse Workshop, St. Teresa Hospital, Hong Kong, September 2009

60. Breast Cancer Treatment Developments by Clinical Trials in Asia

International Surgical Week 2009, Adelaide, Australia, September 2009

61. Progress in Preoperative Therapy in Breast Cancer

The 2nd

International Symposium on the Prevention of Breast Cancers, Taiwan, August 2009

62. 乳癌近十年之治療進展

癌症治療講座, Hong Kong, July 2009

Chow L.W.C.

32

63. Insights Into Evolving Breast Cancer Practice Patterns in China Breast Cancer Congress, Maui, Hawaii, United States of America, July 2009

64. Progress in Preoperative Therapy

Breast Cancer Congress, Maui, Hawaii, United States of America, July 2009

65. 亚洲乳腺癌筛查现状

早期诊断专题研討會, Shenzhen, China, July 2009

66. Network Formation for Sharing of Clinical Data

2009 년 한국유방암학회 춘계학술대회, Jeju, Korea, June 2009

67. Breast Cancer Screening – Biofield Diagnostic System

Manila, April 2009

68. Sentinel Lymph Node Biopsy: Before or After Preoperative Chemotherapy

Asian Oncology Summit (AOS), Singapore, April 2009

69. Surgeon’s Consideration of Image Guided Biopsy for Impalpable Breast Lesions

Taiwan, April 2009

70. New Trials and Chemoprevention in Asia

5th

Annual Scientific Conference of Organisation for Oncology and Translational Research, Macau SAR, February 2009

71. Multidisciplinary Management of Early Breast Cancer in China: Current

Challenges 5

th Annual Scientific Conference of Organisation for Oncology and Translational

Research, Macau SAR, February 2009

72. Bevacizumab: A Blend into Traditional Chemotherapy with Translational

Research 7

th Roche Asia Oncology Forum 2008, Bangkok, November 2008

73. 香港乳腺癌篩查和早期診斷的經驗

早期乳腺癌研討會, Shenzhen, China, November 2008

74. Case Presentation

The 6th

Asia Pacific Oncology Summit, Xian, October 2008

75. Make Right Decisions for Patients – The Progress on The Hormonal Therapy in

Breast Cancer AstraZeneca satellite meeting, Shanghai, China, Oct ober 2008

76. Satellite Symposium – Breast Cancer Surgery

15th

World Congress on breast disease, Shanghai, October 2008

77. Neoadjuvant Trials in Asia

15th

World Congress on beast disease Shanghai, October 2008

78. A New Era of Hormonal Therapy in Breast Cancer Treatment

IX International Aromatase Conference, Shanghai, Oct ober 2008

79. 國際乳腺癌治療新動態

2008 第五屆乳腺癌重慶論壇, Chongqing, China, October 2008

80. Neoadjuvant Hormonal Therapy for Breast Cancer

2008 廣州乳腺癌臨床診治論壇暨第二屆中大一哈佛乳腺癌學術研討會 , Guangzhou, September 2008

Chow L.W.C.

33

81. 賀爾蒙週期變化與乳腺癌的關係

Macau, September 2008

82. Tailoring and expanding the role of erbB2 targeted agents in breast cancer

Annual meeting of the Taiwan Breast Cancer Society, Taipei, September 2008

83. Future Potential of ErbB2 Targeted Therapy in Early BC

Chinese Society of Clinical Oncology Annual Meeting, Shanghai, Aug ust 2008

84. Satellite Symposium

The 9th

Annual conference of Korean Breast Cancer Society, South Korea, June 2008

85. Overview of targeted therapy in breast cancer

國際乳腺癌臨床及病理診斷及治療標準化研討會 , 中國銀川, 5 月 2008 年

86. International clinical practice guidelines for breast cancer

國際乳腺癌臨床及病理診斷及治療標準化研討會 , 中國銀川, 5 月 2008 年

87. Current Treatment of Locally Advanced Breast Cancer in the Asia-Pacific

Region, Including Neoadjuvent Therapy – Challenges and Limitations Scientific and Clinical Expert Panel Meeting, Singapore, March 2008

88. Tyrosine Kinase Inhibitors in Breast Cancer – Current Experience and Future

Perspectives Industry Satellite Symposium, 1

st Asian Breast Cancer Congress, India, February

2008

89. Breast Cancer Management in Hong Kong

21 世紀亞太乳房健康管理研討會, December 2007

90. Lapatinib as A First-line Treatment in Patients with ErbB2 Positive Advanced

or Metastatic Breast Cancer and Biomarkers Analysis Global Breast Cancer Conference, October 2007

91. Neoadjuvant Hormonal Therapy for Breast Cancer

Global Breast Cancer Conference, October 2007

92. Clinical Trial in Asian

6th

Asian Breast Cancer Conference, September 2007

93. 乳腺癌手術治療新進展

澳門腫瘤醫學會第二屆學術年會, Macau, September 2007

94. 乳癌之外物及藥物治療

澳門中華醫學會持續醫學教育課程, Macau, September 2007

95. Timing and Translational aspects in Trastuzumab therapy

6th

Roche Asian Oncology Forum (RAOF), Malaysia, August 2007

96. 乳腺癌生物靶向治療

2007 中國普外科焦點問題學術論壇, China, August 2007

97. Phase 3 Study of Temsirolimus with Letrozole or Letrozole Alone in

Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer Sendai, Japan, February 2007

98. Lapatinib Single Agent in First line Metastatic Breast Cancer

Asiapac Breast Cancer Experts Meeting, Singapore November 2006

Chow L.W.C.

34

99. Future Directions : Clinical Research and New Medicine for Women ’s Cancer

Beijing Women’s Health Summit, Beijing, China, November 2006

100. Creating New Strategies for Cancer Therapy and Prevention

2nd

Annual Conference of the Organisation for Oncology and Translational Research, Tokyo, Japan, November 2005

101. Paradigm Shift in The Management of Breast Cancer

Special Lecture, Shanghai Cancer Hospita l, Shanghai, China, October 2004

102. Clinical Experience on COX-2 Inhibition in Breast Cancer

1st

Annual Conference, Organisation for Oncology and Translational Research Hong Kong, October 2004

103. Keynote Lecture: Current Direction of COX-2 Inhibition in Breast Cancer

Second Asia Pacific Oncology Summit: Commitment to Advancing the Treatment of Solid Tumors, Suzhou, China, October 2004

104. New Paradigm in the Treatment of Breast Cancer

2004 National Congress on the Diagnosis and Management of Breast Cancer The Breast Society of the Chinese Medical Association , Chongqing, China, September 2004

105. Neoadjuvant Therapy for Breast Cancer

Tohoku University Faculty of Medicine, Sendai, Japan, July 2004

106. Neoadjuvant Therapy for Breast Cancer

Inaugural Stanford-Hong Kong Oncology Teleconference and Seminar – Update in Breast Cancer Investigation and Treatment, Hong Kong, April 2004

107. Neoadjuvant Hormonal Therapy

Key Advances in the Treatment of Breast Cancer, Hong Kong, February 2004

108. Clinical Management of Women with BRCA1 or BRCA2

Asian Breast Cancer Conference, Taipei, February 2004

109. To Screen or Not To Screen: The Evidences

10th

Hong Kong International Cancer Congress, Hong Kong, November 2003

110. Stereotatic Breast Biopsy with Vacuum Assisted Minimally Invasive Biopsy

Technology First Mammotome Asia Pacific Summit Meeting, Shanghai, China November 2003

111. Celecoxib Anti-aromatase Neoadjuvant (CAAN) Trial for Locally Advanced

Breast Cancer: Preliminary Report First Asia Pacific Oncology Summit, Hanoi, China, October 2003

112. Phase II Study on An “All-oral” Regimen of Capecitabine, Idarubicin and

Cyclophosphamide in Metastatic Breast Cancer; -Possibility and Efficacy- The 2nd Roche Asia Oncology Forum, Taipei, October 2003

113. Introduction to Breast Mapping

Radioguided Breast Cancer Surgery Symposium, The Breast Cancer Society of Taiwan, November 2002

Chow L.W.C.

35

114. Celebrex Anti-aromatase Neoadjuvant Trial for Locally Advanced Breast Cancer VI International Aromatase Conference - Aromatase 2002: The new millennium, Kyoto, October 2002

115. All-oral Combination Therapy and Practical Patient Management with Xeloda

1st

Roche Asia Oncology Symposium, Shanghai, China, September 2002

116. Current Treatment of Breast Cancer

Making the Difference in the Management of Breast Cancer, Pharmacia Symposium, Xian, China, June 2002

117. Radioguided Surgery for Breast Cancer

Chinese Medical Association, Breast Cancer Group, Beijing, China, March 2002

118. Sentinel Biopsy for Breast Cancer

Hong Kong Surgical Forum, Hong Kong, January 2002

119. Sentinel Biopsy for Breast Cancer

Eight Joint Shanghai/Hong Kong Surgical Convention, Shanghai, January 2002

120. Breast Cancer in Hong Kong

The 5th

Symposium of the Shanghai Anti -Cancer Association, Yangzhou, November 2001

121. Locally Advanced Breast Cancer

The 13th

Biennial Congress of the Asian Surgical Association, Singapore, November 2001

122. Sentinel Lymph Node Biopsy in Breast Cancer Management

8th

Hong Kong International Cancer Congress, Hong Kong, September 2001

123. Debate on Breast Cancer Screening

8th

Hong Kong International Cancer Congress, Hong Kong, September 2001

124. Sentinel Lymph Node Biopsy in BC Management – Theory and Practice

1st

Meeting of the Chinese Breast Cancer Society, Chongqing, China, September 2001

125. Management of Breast Cancer

Hong Kong Medical Association CME Program 2001, , Hong Kong, July 2001

126. The Epidemiology of Breast Cancer in Hong Kong

The 3rd

Biennial Meeting of the Asian Breast Cancer Society, Seoul, Korea, June 2001

127. Epirubicin-Based Neoadjuvant and Adjuvant Treatment of Breast Cancer

5th

International Conference of the Asian Clinical Oncology Society & the 6th Taiwan Joint Cancer Conference, Taipei, April 2001

128. Management of Impalpable Breast Cancer

The 2nd

Cross-Strait & World Chinese General Surgical Congress, Chinese Surgical Society, Wuhan, China, November 2000

129. Management of Locally Advanced Breast Cancer in Hong Kong

Taipei International Breast Cancer Symposium, Taipei, October 2000

130. Breast Cancer Screening – an Overview

Symposium on Molecular Medicine for the Practising Clinicians, Centre of Endocrinology & Diabetes, University of Hong Kong, May 2000

Chow L.W.C.

36

131. Local Experience in the Use of Xeloda in the Management of Metastatic Breast

Cancer Scientific Symposium, Hong Kong Anticancer Society, April 2000

132. Tamoxifen in Prevention of Breast Cancer

6th

Hong Kong International Cancer Congress, November 1999

133. Breast Conservation Surgery

6th

Hong Kong International Cancer Congress, November 1999

134. Mechanism of Actions of TCM: Laboratory Studies

6th

Hong Kong International Cancer Congress, November 1999

135. Tumour Markers in the Management of Breast Cancer

12th

Biennial Congress, Asian Surgical Association and Royal Australasian College of Surgeons, Brisbane, Australia, March 1999

136. Critical Evaluation and Practical Application of Prognostic Factors

Advanced Workshop in Breast Cancer Management, European School of Oncology and Kwong Wah Hospital, Hong Kong, November 1998

137. The effect of Polysaccharide Peptide (PSP) in breast cancer

Symposium on Advances in Traditional Chinese Medicine, University of Hong Kong, June 1998

138. Application of Chemosensitivity Testing in Breast Cancer

14th

Asian Pacific Cancer Congress and 4th

Hong Kong International Cancer Congress, Hong Kong, November 1997

139. Management of Ductal Carcinoma In-Situ

14th

Asian Pacific Cancer Congress and 4th

Hong Kong International Cancer Congress, Hong Kong, November 1997

140. Prognostic Factors of Breast Cancer

110th

Anniversary & Medical Congress, University of Hong Kong, Hong Kong, October 1997

141. Predictors of Response of Breast Cancer

11th

Biennial Congress, Asian Surgical Association, Hong Kong, March 1997

142. The Management of Recurrent Breast Cancer

11th

Biennial Congress, Asian Surgical Association, Hong Kong, March 1997

143. Surgical Treatment of Invasive Breast Cancer in Hon g Kong

Breast Cancer Symposium, 16th Annual Meeting, Chinese Medical Association, Taiwan, June 1996

144. Treatment of Breast Cancer in Hong Kong

Japanese Breast Cancer Society, Osaka, 1996

145. Use of Prognostic Factors in Patient Management - Clinician’s Point of View

Workshop on Breast Diseases, Hong Kong Pathology Society, May 1995

146. Extent and Limits of Surgery - Breast Cancer

Surgical Forum, The University of Hong Kong, July 1994